奧比中光(688322.SH):目前在工業三維測量、工業機器人等領域已成功進行了技術商業化
格隆匯5月16日丨奧比中光(688322.SH)於2023年5月15日下午16:00-17:00召開業績説明會,問答環節中,就“公司工業領域的客户有哪些?公司提供哪些產品和技術?”,公司回覆稱,公司3D視覺感知技術在工業業務板塊下游主要面向科研院所及工業製造等行業需求,目前在工業三維測量、工業機器人等領域已成功進行了技術商業化,驗證了商業化可行性及需求空間。
公司將其作為貫穿短中長期的業務發展戰略之一,結合工業領域裝備製造國產化進程,穩步推動業務拓展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.